These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 34403364)
1. Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS. Yu J; Wang S; Shi W; Zhou W; Niu Y; Huang S; Zhang Y; Zhang A; Jia Z JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403364 [TBL] [Abstract][Full Text] [Related]
2. Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. Savoia C; Arrabito E; Parente R; Nicoletti C; Madaro L; Battistoni A; Filippini A; Steckelings UM; Touyz RM; Volpe M Hypertension; 2020 Dec; 76(6):1753-1761. PubMed ID: 33070664 [TBL] [Abstract][Full Text] [Related]
3. The protective effects of polysaccharide extract from Xin-Ji-Er-Kang formula on Ang II-induced HUVECs injury, L-NAME-induced hypertension and cardiovascular remodeling in mice. Ding L; Cheng P; Wang L; Hu J; Zhang YX; Cai GW; Huang GY; Gao S BMC Complement Altern Med; 2019 Jun; 19(1):127. PubMed ID: 31196042 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of prolyl hydroxylase domain-containing protein downregulates vascular angiotensin II type 1 receptor. Matsuura H; Ichiki T; Ikeda J; Takeda K; Miyazaki R; Hashimoto T; Narabayashi E; Kitamoto S; Tokunou T; Sunagawa K Hypertension; 2011 Sep; 58(3):386-93. PubMed ID: 21825224 [TBL] [Abstract][Full Text] [Related]
10. Nebivolol alleviates aortic remodeling through eNOS upregulation and inhibition of oxidative stress in l-NAME-induced hypertensive rats. Wang Y; Zhang F; Liu Y; Yin S; Pang X; Li Z; Wei Z Clin Exp Hypertens; 2017; 39(7):628-639. PubMed ID: 28640644 [TBL] [Abstract][Full Text] [Related]
11. Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats. Stennett AK; Qiao X; Falone AE; Koledova VV; Khalil RA Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H745-55. PubMed ID: 19151255 [TBL] [Abstract][Full Text] [Related]
13. HDAC5 inhibition reduces angiotensin II-induced vascular contraction, hypertrophy, and oxidative stress in a mouse model. Bai L; Kee HJ; Choi SY; Seok YM; Kim GR; Kee SJ; Kook H; Jeong MH Biomed Pharmacother; 2021 Feb; 134():111162. PubMed ID: 33360932 [TBL] [Abstract][Full Text] [Related]
14. ROS and endothelial nitric oxide synthase (eNOS)-dependent trafficking of angiotensin II type 2 receptor begets neuronal NOS in cardiac myocytes. Jang JH; Chun JN; Godo S; Wu G; Shimokawa H; Jin CZ; Jeon JH; Kim SJ; Jin ZH; Zhang YH Basic Res Cardiol; 2015 May; 110(3):21. PubMed ID: 25804308 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hiyoshi H; Yayama K; Takano M; Okamoto H Hypertension; 2005 May; 45(5):967-73. PubMed ID: 15837834 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury. Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645 [TBL] [Abstract][Full Text] [Related]
17. Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Brede M; Roell W; Ritter O; Wiesmann F; Jahns R; Haase A; Fleischmann BK; Hein L Hypertension; 2003 Dec; 42(6):1177-82. PubMed ID: 14581297 [TBL] [Abstract][Full Text] [Related]
18. NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Siragy HM; Inagami T; Carey RM Am J Physiol Regul Integr Comp Physiol; 2007 Oct; 293(4):R1461-7. PubMed ID: 17670863 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358 [TBL] [Abstract][Full Text] [Related]
20. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease. Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]